key: cord-0781937-047aaa7l authors: Tejada Cifuentes, Francisco; Lloret Callejo, Ángeles; Tirado Peláez, María José title: COVID-19 vaccines and herpes infection() date: 2021-11-12 journal: Med Clin (Engl Ed) DOI: 10.1016/j.medcle.2021.05.005 sha: ce6debfe9823abe9371a9ab18638ffe96f20383f doc_id: 781937 cord_uid: 047aaa7l nan This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. To date, numerous adverse reactions have been described, the vast majority of which are mild (fever, headache, myalgia, pain at the injection site, etc.) and self-limiting in time. Immune thrombocytopenia is the most serious adverse effect of those described, with a very low incidence, although the consequences can be fatal. This adverse reaction has been responsible for suspending vaccination campaigns. The possible mechanism of this thrombocytopenia is unclear, although a possible autoimmune mechanism has been postulated against platelet factor 4, similar to that of heparin-induced thrombocytopenia 1,2 . Reviewing the pharmacovigilance reports of the Spanish Agency for Medicines and Medical Devices (AEMPS), until April no case of herpes disease has been reported following vaccination with any of these three vaccines (Pfizer, Moderna and AstraZeneca) 3 . Of the cases described in this letter, four have been notified to https://www.notificaram.es and three by the traditional yellow card method (the rest are pending notification). This letter describes 29 cases of herpes virus infection in patients recently vaccinated with the Comirnaty vaccine and COVID-19 Vaccine Moderna in the Integrated Care Management (ICM) of Albacete. This data represents an incidence of 0.836 cases per 1,000 vaccinated people. 55% of the cases have been seen in women and the mean age of the patients has been 66 years (34-95 years). In 15 patients, symptoms developed after the first dose of vaccine (8.7 days on average) and in 14 patients they developed after the second dose (24.7 days on average after the second dose). The site of the lesions is as follows: 13 patients presented with herpes zoster in the thoracic region, eight in the abdominal area, three herpes zoster in the first trigeminal branch with ocular involvement, two herpetic keratitis and one case each in the buttock, leg in dermatome S1 and pelvis dermatome L1. In one of the cases of herpetic keratitis, after treatment with valacyclovir, and after significant improvement, there was a considerable worsening after the administration of the second dose of the vaccine. This patient was being treated with an interleukin 17A inhibitor, secukinumab. At the time of the study, 34,672 people had been vaccinated in this ICM, of whom 93.1% of patients who developed herpes were vaccinated with the Comirnaty vaccine and 6.1% with the COVID-19 Vaccine Moderna. This result is consistent with the vaccination data, since 85.6% of the population in this health area has been vaccinated with Comirnaty, 3.1% with Moderna, and 11.3% with AstraZeneca. In view of these results, it does not appear that the development of herpes infection is specifically related to one of the vaccines used, although it is noteworthy that no patients vaccinated with AstraZeneca have been found. Our data agree with a recently published case series in Israel 4 , with six patients who developed herpes after vaccination with Comirnaty, although their study is conducted only among rheumatic patients. It is well known that immunosuppressed situations can favour herpes reactivation, although this mechanism does not seem to be triggered by the COVID-19 vaccine 5 . Reactivation could be related to the inflammatory process that develops after vaccination. There are few patients, and this fact will have to be confirmed with larger case series, but this letter is intended to be a wake-up call so that all health professionals remain attentive to any adverse reaction that may occur (even if it is only a suspicion) and that shows a causal and temporal relationship with the administration of the vaccine. These preliminary results will be complemented by a follow-up until the end of the vaccination campaign, especially with regard to whether the Vaxzevria vaccine is involved in the occurrence of this adverse event. Funding This article has not received any type of funding. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination Vacunas Covid-19 Informe de Farmacovigilancia. Número 4. Agencia Española de Medicamentos y Productos Sanitarios Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series Clinical Features of Varicella-Zoster Virus Infection The authors declare no conflict of interest.